The Rest of the World segment reported a growth of 28% to $729.2 million during 4Q16 from $570.5 million during 4Q15.
The North America segment reported a growth of 22% to $1.6 billion during 4Q16 from $1.3 billion during 4Q15.
Mylan (MYL) released its 4Q16 and 2016 earnings results on March 1, 2017. The company reported revenues of $3.3 billion, a 13% increase as compared to 4Q15 revenues of $2.5 billion.
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) expect to secure FDA approval for Dupixent (dupilumab) as a monotherapy for moderate-to-severe atopic dermatitis by March 29, 2017.
In 2017, Regeneron Pharmaceuticals (REGN) expects data from the Phase 2 trial evaluating Dupixent as a treatment option for eosinophilic esophagitis.
Wall Street analysts have projected that Regeneron Pharmaceuticals’s (REGN) 2017 revenues would be ~$5.5 billion, which represents year-over-year growth of ~13.2%.
For fiscal 2016, Regeneron Pharmaceuticals (REGN) reported diluted non-GAAP earnings per share of ~$11.32.
Of the 25 analysts covering Regeneron Pharmaceuticals (REGN) in February 2017, seven rated the company as a “strong buy,” five rated it as a “buy,” and 13 rated it as a “hold.”
Gilead’s liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.
The oncology portfolio includes the drug Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL).
Gilead Sciences (GILD) reported a decrease in revenues by ~7% to $30.4 billion during 2016 as compared to $32.6 billion during 2015.
Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others.
On a capital-structure-neutral and excess-cash-adjusted basis, Gilead currently trades at ~3.9x, which is lower than the industry average of ~9.8x.
In 2016, AstraZeneca’s (AZN) Symbicort reported revenues close to $3.0 billion, which is a YoY fall of about 10.0% on a CER basis.
Since 2012, AstraZeneca (AZN) has launched new products in its three main therapeutic areas of diabetes and respiratory diseases, cardiovascular diseases, and oncology.
For 2016, AstraZeneca (AZN) reported revenues of about $5.8 billion for its emerging markets business, which is a YoY (year-over-year) rise of about 6.0%.
AstraZeneca (AZN) has projected that its 2017 revenues will fall in the low to mid-single digits YoY. Loss of patent exclusivity for Crestor affected 2016 revenues.
AstraZeneca (AZN) has projected that its 2017 core EPS (earnings per share) will fall in the low to mid-teens YoY (year-over-year).
Of the 34 analysts covering AstraZeneca in February 2017, eight have rated it a “strong buy,” and 13 have rated it a “buy.”
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.